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Theaﬂavin, a major constituent of black tea, possesses biological functions such as the antioxidative, antiviral, and anti-inﬂam-
matory ones. The purpose of this study was to verify whether theaﬂavin reduces focal cerebral ischemia injury in a rat model
of middle cerebral artery occlusion (MCAO). Male Sprague-Dawley rats were anesthetized and subjected to 2hours of MCAO
followed 24hours reperfusion. Theaﬂavin administration (5, 10, and 20mg/kg, IV) ameliorated infarct and edema volume.
Theaﬂavin inhibited leukocyte inﬁltration and expression of ICAM-1, COX-2, and iNOS in injured brain. Phosphorylation of
STAT-1, a protein which mediates intracellular signaling to the nucleus, was enhanced 2-fold over that of sham group and was in-
hibited by theaﬂavin. Our study demonstrated that theaﬂavin signiﬁcantly protected neurons from cerebral ischemia-reperfusion
injury by limiting leukocyte inﬁltration and expression of ICAM-1, and suppressing upregulation of inﬂammatory-related proox-
idative enzymes (iNOS and COX-2) in ischemic brain via, at least in part, reducing the phosphorylation of STAT-1.
Copyright © 2006 Fei Cai et al. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Acute ischemic stroke is the leading cause of adult disabil-
ity and it is also an important cause of death in industrial-
ized countries with a high incidence aﬀecting up to 0.2% of
the population every year [1]. Although pathologic mecha-
nisms leading to cerebral ischemic injury remained unclear,
it has been emphasized that inﬂammatory process had fun-
damental roles in both the etiology of ischemic cerebrovas-
cular disease and the pathophysiology of cerebral ischemia
[2, 3]. Neutrophils are critically involved in the early stage
of inﬂammatory reaction after ischemia, initiating scavenger
functions which are later subsumed by macrophages [4, 5].
Endothelial cells actively participate in inﬂammatory events
by regulating leukocyte recruitment via the expression of
inﬂammation-related genes such as ICAM-1, VCAM-1, E-
selectin, IL-6, IL-8, and cyclooxygenase-2 [6, 7].
Cyclooxygenase (COX), a rate-limiting enzyme in the
metabolism of arachidonic acid into prostanoids, produces
PGH2 which in subsequent steps gives rise to PGs with vari-
ousphysiologicalfunctions[8–10].Ithasbeendemonstrated
inpreviousreportsthatcerebralischemiaupregulatedthein-
ducible form of COX (COX-2) in neurons, glial cells and in-
ﬁltrating leukocytes in injured brain [11–13]. Inhibition of
COX-2 activity during or after ischemia and genetic dele-
tion of COX-2 reduce infarct volume [14]. In addition, neu-
ronal overexpression of COX-2 increases cerebral infarction
[15, 16]. These observations suggest that COX-2 plays a dele-
terious role in cerebral ischemia. Interestingly, nitric oxide
produced by inducible form of nitric oxide synthase (iNOS)
has been found to positively regulate COX-2 activity in focal
cerebralischemia[17].CerebralischemiaenhancediNOSex-
pressioninneurons,endothelial cells,andmicroglia[18,19].
i N O Sc l e a r l yp l a y sar o l ei ns t r o k eo u t c o m e ,a se v i d e n c e db y
its selective inhibition in the rat model of MCAO or its ge-
netic deletion [20, 21].
STAT-1 is a member of the signal transducers and acti-
vators of transcription proteins family (STATs), which me-
diate intracellular signaling initiated at cytokine cell surface
receptors and transmit to the nucleus. The C terminal do-
mains of STAT proteins contain a transcriptional transacti-
vationdomainwhichisessentialformaximalSTATfunction.2 Mediators of Inﬂammation
Recent study has shown that myocardial ischemia activates
JAKs, followed by recruitment of STAT-1, resulting in tran-
scriptional upregulation of inducible nitric oxide synthase
(iNOS) and cyclooxygenase-2 (COX-2) [22–24]. It has been
demonstrated that focal cerebral ischemia induced STAT-1
activation[25]andSTAT-1knockoutmicedevelopedsmaller
lesions and less pronounced neurological deﬁcit following
transient focal cerebral ischemia [26].
Catechins andtheaﬂavinsaretwogroupsofnaturalpoly-
phenols found in green tea and black tea, respectively [27].
Theseteapolyphenolspossessabroadspectrumofbiological
functions such as antioxidative, antibacteria, antitumor, an-
tiviral, anti-inﬂammatory, and cardiovascular protection ac-
tivities [28–31]. It has been reported that epigallocatechin-3-
gallate (EGCG), a major constituent of catechins, may atten-
uate cerebral ischemia-reperfusion injury in rats [32] and it
was also a potent inhibitor of STAT-1 phosphorylation [33].
Therefore, the present study was undertaken to evaluate the
neuronal protective potential of theaﬂavin (TF1), a major
constituentoftheaﬂavins,inmiddlecerebralarteryocclusion
(MCAO) induced focal cerebral ischemia-reperfusion model
in rats.
MATERIALS AND METHODS
Experimentalprotocolanddrug
Male Sprague-Dawley rats weighing 220–260g were housed
at room temperature under a controlled 12h light/dark cy-
cle and allowed access to food and water ad libitum. All
experiments were performed as approved by the institu-
tional animal care and use committee. Rats were divided into
six groups and each group had ten animals. The ﬁrst was
vehicle-treated group, that is, ischemia was induced for 2h
of MCAO followed by reperfusion for 24h. The second was
sham group. The theaﬂavin (a pure natural product collec-
tion provided by MicroSource Discovery System Inc, Gay-
lordsville, Conn)-treated groups were separated into a low
dosage group (TF1, 5mg/kg), a middle dosage group (TF1,
10mg/kg), and a high dosage group (TF1, 20mg/kg). The
intravenous injection of theaﬂavin was conducted directly
before the reperfusion. The sixth was nimodipine-treated
group (1mg/kg, IP). All other chemicals and reagents were
of the highest analytical grades available locally.
Middlecerebralarteryocclusioninducedfocal
cerebralischemia
Focal cerebral ischemia was produced by occluding the left
middle cerebral artery according to the methods by Longa et
al [34]. Brieﬂy, the rats were anaesthetized with Chloral hy-
drate (400mg/kg, IP). Through a midline neck incision, the
left common and external carotid artery were isolated from
muscles and coagulated. A 3-0 nylon suture with a blunted
tip was inserted into the internal carotid through the exter-
nal carotid artery stump and advanced up to 21mm or till
resistance was left. After 2h of MCAO, the suture was re-
moved to restore blood ﬂow. In sham group, the same sur-
gical procedure was performed except that the suture was in-
troduced into the external carotid artery but not advanced.
After surgery, the incision was sutured and the rats were
returned to their cage with free access to water and food.
Twenty-four hours after reperfusion, rats were sacriﬁced by
rapiddecapitationunderdeepanesthesiaandthebrainswere
taken out for biochemical estimations.
Infarctandedemavolume
Twenty-four hours after reperfusion, whole brains were
rapidly removed. Immediately after being weighed, the
brains were sliced into 2-mm-thick coronal sections and
stained with 2%2,3,5-triphenyltetrazoliumchloride (TTC,
Sigma-Aldrich) at 37◦C for 30minutes in the dark, fol-
lowed by ﬁxation with 10% formalin at room temperature
overnight. The sections were photographed with a digital
camera (Kodak DC240, USA) connected to a computer. The
unstained areas, deﬁned as infarct tissue, were calculated by
using an image analysis program (Adobe Photoshop 5.0CS).
The infarct volume was calculated by measuring the un-
stainedareaineachslice.Edemacorrectionofinfarctvolume
was done using the equation, volume correction = (infarct
volume × contralateral volume)/ipsilateral volume. The vol-
umes of both the hemispheres were calculated from which
edema volume was calculated by subtracting the contralat-
eral volume from the ipsilateral volume.
Measurementoflipidperoxidation
The estimate of lipid peroxidation of the cerebral cortex
was determined by measuring the formed malondialdehyde
(MDA). Brieﬂy, brain tissues were homogenized (10%, w/v)
with cold 1.5% KCl. The homogenate was mixed with a 1%
phosphoric acid and 6% TBA (Sigma-Aldrich) aqueous so-
lution. The mixture was heated for 45minutes in a boiling
water bath. After cooling, n-butanol was added and mixed
vigorously. The absorbance of the butanol phase was mea-
sured at 525nm. A serially diluted MDA (Sigma-Aldrich) so-
lution was prepared and used as a standard. The data (MDA)
was expressed as nmol/mg protein.
Myeloperoxidaseassay
The activity of myeloperoxidase (MPO) was determined as
an indicator of PMNs migration, as previously described
[35]. The method of assaying MPO activity was according to
the guide of the assay kit (Nanjing Jiancheng Bioengineering
Co Ltd, China).
Immunohistochemistrydetection
The procedures were processed according to the protocols
recommended for ICAM-1, iNOS, and COX-2 immuno-
histochemistry kit. Following deparaﬃnization and rehy-
dration, the cortices sections were exposed to 3% hydro-
gen peroxide for 10minutes to bleach endogenous perox-
idases. Then microwave oven-based antigen retrieval wasFei Cai et al 3
performed. Slides were probed with either anti-ICAM-1 (1 :
100, rat monoclonal, Santa Cruz Biotechnology), anti-iNOS
(1 : 100, rat polyclonal, Santa Cruz Biotechnology), or anti-
COX-2 (1 : 50, rat monoclonal, Santa Cruz Biotechnol-
o g y )f o r1h o u ra t3 7 ◦C, washed 3 times in PBS, incubated
with biotin-labeled anti-rat IgG for 1 hour at 37◦C, respec-
tively. Incubation with PBS instead of the primary antibody
served as a negative control. After washing in PBS, tissues
were visualized with 3, 3 -diaminobenzidine tetrahydrochlo-
ride (DAB) and counterstained with hematoxylin. Finally,
the sections were dehydrated in graded ethanol, immersed in
xylene and coverslipped. In specimens the positive cells were
counted in cortex in ten randomly selected areas from each
case and expressed as number of immunopositive/mm2.R e -
sults are presented as mean ±SEM.
RT-PCR
Total RNA was extracted from cortex using TRIzol reagent
(Sigma Co). cDNA was synthesized according to the man-
ufacturer’s instruction of reverse transcription kit (GIBCO-
BRL, USA), and then ampliﬁed with a multiplex PCR kit
(GIBCO-BRL, USA). Conditions for ampliﬁcation were as
follows: initial denaturation for 2minutes at 94◦C, 35 cy-
cles of 94◦C for 30 seconds, 60◦C for 45 seconds, 72◦Cf o r
60 seconds, and a ﬁnal extension stop at 72◦Cf o r7m i n u t e s .
The rat speciﬁc primers (sense and antisense primers) for
iNOS, COX-2, and β-actin were 5 -CGGTGCTGTATTTC-
CTTACGAGGCGAAGAAGG-3  and 5 -GGTGCTGTCTG-
TTAGGAGGTCAAGTAAAGGGC-3  (iNOS,259bp); 5 -C-
CATGTCAAAA-CCGTGGTGAATG-3  and 5 -A-TGGGA-
GTTGGGCAGTCATCAG-3  (COX-2,374bp); 5-ATGGAT-
GACGATATCGCTG-3 and 5-ATGAGGTAGTCTGTCAG-
GT-3 (β-actin, 568bp), respectively. Reaction products were
then separated on a 1.5% agarose gel, stained with ethidium-
bromide, and visualized by UV transillumination. HPIAS-
1000 software analysis system was used to determine the rel-
ative absorbance of mRNA expression.
Westernblotanalysis
The cortices of brains were removed and used for West-
ern analysis. Protein concentrations were determined us-
ing the Bio-Rad protein assay kit (Bio-Rad, Hercules, Calif)
a n da l ls a m p l e sw e r ea d j u s t e dt oa ne q u a lp r o t e i nc o n -
tent before analysis. Samples (30μg of total protein) were
separated on 8% denaturing polyacrylamide gel. Following
electrophoresis, proteins were transferred to a nitrocellulose
membrane (80V, 90minutes; transfer buﬀer 25mM Tris,
190mM glycine, 20% methanol, 0.5% sodium dodecyl sul-
fate) by an electroblotter (Bio-rad). After being blocked for
two hours at room temperature in blocking buﬀer (5% non-
f a tm i l ki n2 0 m MT r i s /HCl, pH 7.6, 140mM NaCl, 0.5%
Tween 20), membranes were incubated over night at 4◦C
with primary antibodies against antiphospho-STAT-1Tyr-
701 (Zymed, South San Francisco, Calif), or anti-STAT-1
(Santa Cruz Biotechnology, Santa Cruz, Calif). Membranes
were then washed (in 20mM Tris/HCl, pH 7.6, 140mM
NaCl, 0.1% Tween 20) and incubated with a peroxidase-
conjugated secondary antibody at room temperature for
50minutes. The immunoblots were visualized using Western
blotting luminal reagent (Cell Signal Corp). The density of
protein band was scanned and analyzed with an image ana-
lyzer.
Statisticalanalysis
Unless otherwise stated, all the results were ﬁnally presented
as means ± SEM. Statistical diﬀerences between diﬀerent
groups were assessed by a one-way analysis of variance and
Student-Newman-Keuls test. P value less than .05 was con-
sidered statistically signiﬁcant.
RESULTS
Effectoftheaﬂavinoncerebralinfarctionandedema
Infarct volume was measured in the coronal brain sec-
tions which were stained with TTC. Two hours of MCAO
and 24hours of reperfusion showed an infarct volume of
220.87 ± 27.42mm3. The infarct volume was decreased to
183.49 ± 19.33mm3, 139.06 ± 11.28mm3, and 118.25 ±
10.36mm3 in 5, 10, and 20mg/kg theaﬂavin-treated rats,
respectively, (Figure 1). Theaﬂavin at the doses of 10 and
20mg/kg produced 40.79±8.71% and 52.30±9.79% reduc-
tion in infarct volume, respectively, as compared to vehicle-
treated group (P<. 01, Figure 1). Two hours of MCAO and
24hours of reperfusion resulted in 133.63 ± 11.07mm3 in-
crease in the ipsilateral volume due to edema. Theaﬂavin at
the doses of 5, 10, and 20mg/kg resulted in reduction of
edema volume to 98.61 ± 25.34mm3,6 1 .37 ± 14.13mm3,
and 51.25 ± 9.97mm3 of ipsilateral hemisphere, respec-
tively (Figure 1). Theaﬂavin at the doses of 10 and 20mg/kg
showed48.63±7.84%and55.04±8.01%reductioninedema
volume, respectively as compared to vehicle-treated group
(P<. 01, Figure 1). Nimodipine-treatment also reduced the
infarct and edema volumes. The infarct and edema volumes
of Nimodipine-treated group were 110.39 ± 10.17mm3 and
55.26 ±10.65mm3,r e s p e c t i v e l y( P<. 01, Figure 1).
EffectoftheaﬂavinonMDA
The level of MDA signiﬁcantly increased in the vehicle-
treated group more than in the sham group. As compared
to the vehicle-treated group, the levels of MDA signiﬁcantly
decreased in the theaﬂavin and nimodipine-treated groups
(P<. 01, Table 1). The theaﬂavin-treated group (20mg/kg)
had the same eﬀect as compared to the nimodipine-treated
group (P>. 05). However, the MDA levels of theaﬂavin-
treated groups were still higher than that of sham group.
Effectoftheaﬂavinoninﬂammatoryinjuryof
cerebralischemia
Inﬁltration of leukocytes to CI/R-injured tissue provides
predominant sources for MPO, an important prooxidative4 Mediators of Inﬂammation
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Figure 1:(a)RepresentativecoronalbrainsectionsstainedwithTTCafter2hoursofMCAOand24hoursofreperfusionshowinginfarction.
Dark-colored region in the TTC stained sections indicated nonischemic portion of brain and pale-colored region indicated ischemic portion
of brain. Theaﬂavin and nimodipine-treatment reduced infarct volume. (b) Volume of infarction after 2hours of MCAO and 24hours of
reperfusion in vehicle, theaﬂavin (5, 10, and 20mg/kg) and nimodipine (1mg/kg)-treated rats. (c) Volume of edema after 2hours of MCAO
and 24hours of reperfusion in vehicle, theaﬂavin (5, 10, and 20mg/kg) and nimodipine-treated (1mg/kg) rats, ∗∗P<. 01 as compared to
the vehicle-treated group.
Table 1: Eﬀect of theaﬂavin on MDA and MPO activities (x±sn=
10).
Parameters Dose
(mg· kg−1)
MDA
(nmol/mg protein)
MPO
(U· g−1)
Vehicle —4 .13 ±1.56 2.13 ±0.69
Sham —1 .45 ±0.09 0.34 ±0.12
TF1 53 .12 ±1.62∗∗ 1.92 ±0.51
TF1 10 2.77 ±1.09∗∗ 1.43 ±0.45∗∗
TF1 20 2.34 ±1.13∗∗ 1.21 ±0.39∗∗
Nimodipine 12 .41 ±1.10∗∗ 1.24 ±0.33∗∗
∗∗denotes that P<. 01 versus the vehicle-treated group.
enzyme responsible for oxidative stress in CI/R-injured
brain. In this study, the MPO activity was relatively low in
the sham group, and signiﬁcantly increased in the vehicle-
treated group. Treatment with 10 and 20mg/kg theaﬂavin
signiﬁcantly reduced MPO activity in the CI/R-injured cere-
bral tissue. Nimodipine-treatment also reduced MPO activ-
ity (Table 1).
EffectoftheaﬂavinonICAM-1,iNOS,andCOX-2
proteinproduction
TheproteinexpressionsofICAM-1,iNOS,andCOX-2inthe
ischemic cortex of the vehicle-treated group signiﬁcantly in-
creased compared with those of the sham group. The expres-
sion of ICAM-1 was obviously identiﬁed on the microvascu-
lar endothelial cells in the ischemic hemisphere (Figure 2).
The positive cells of iNOS and COX-2 were found with
brown cytoplasma and predominantly located within the
neurons, glial cells, and inﬁltrating leukocytes (Figures 3,
4). The protein expressions of ICAM-1, iNOS, and COX-
2 decreased dose dependently in theaﬂavin-treated groups
(Table 2). Eﬀect of 20mg/kg theaﬂavin was similar to that of
nimodipine (1mg/kg).
EffectoftheaﬂavinonCOX-2andiNOS
mRNAexpressions
The mRNA expressions of COX-2 and iNOS were analyzed
by RT-PCR. The brain tissue obtained from the sham group
showed low mRNA expression levels of COX-2 and iNOS.
After2hoursofMCAOand24hreperfusion,theexpressions
of COX-2 and iNOS remarkably increased in ischemic hemi-
sphere in the vehicle-treated group as compared with the
sham group. Theaﬂavin-treatment could reduce molecule
mRNA expressions dose dependently and nimodipine also
reduced the expressions of molecule mRNA (Figures 5, 6).
EffectoftheaﬂavinonSTAT-1proteinexpression
The levels of STAT-1 phosphorylation on tyrosine 701 were
markedly enhanced in brains subjected to 2hours of MCAO
followed 24hours reperfusion. However, the brains treatedFei Cai et al 5
Table 2: ICAM-1, iNOS, and COX-2 protein production in vehicle and theaﬂavin-treated groups (x ±sn= 10).
Parameters Dose
(mg· kg−1)
ICAM-1
(number of immunopositive/mm2)
iNOS
(number of immunopositive/mm2)
COX-2
(number of immunopositive/mm2)
Vehicle — 166.21 ±34.26 61.21 ±20.34 67.41 ± 22.29
Sham —1 2 .36 ±7.09 13.24 ±6.98 10.36 ±7.06
TF1 59 7 .28 ±24.67∗∗ 42.11 ±21.06∗∗ 39.14 ±21.74∗∗
TF1 10 63.12 ±22.30∗∗ 31.21 ±16.57∗∗ 28.57 ±12.39∗∗
TF1 20 32.17 ±16.55∗∗ 24.88 ±14.89∗∗ 21.36 ±14.21∗∗
Nimodipine 13 8 .66 ±19.87∗∗ 24.31 ±15.33∗∗ 23.61 ±12.58∗∗
∗∗denotes that P<. 01 versus the vehicle-treated group.
(a) (b)
Figure 2: Immunohistochemical staining of ICAM-1 in brain tissues of (a) vehicle-treated rats and (b) theaﬂavin-treated rats (20mg/kg),
SP×400.ICAM-1proteinismainlyexpressedonthemicrovascularendothelialcells.ICAM-1expressiondecreasesdramaticallyintheaﬂavin-
treated groups. Scale bar = 10μm.
(a) (b)
Figure 3: Immunohistochemical staining for iNOS protein expression in (a) vehicle-treated rats and (b) theaﬂavin-treated rats (20mg/kg),
SP × 400. The number of iNOS immunoreactive positive cells in theaﬂavin-treated groups is signiﬁcantly less than that of vehicle-treated
group. Scale bar = 10μm.
(a) (b)
Figure 4:ImmunohistochemicalstainingforCOX-2proteinexpressionin(a)vehicle-treatedratsand(b)theaﬂavin-treatedrats(20mg/kg),
SP × 400. The number of COX-2 immunoreactive positive cells in theaﬂavin group is signiﬁcantly less than that of vehicle-treated group.
Scale bar = 10μm.6 Mediators of Inﬂammation
600bp
400bp
200bp
12 3 4 5 6 7
(a)
0
50
100
150
200
250
300
350
400
450
O
p
t
i
c
a
l
d
e
n
s
i
t
y
(
%
o
f
S
h
a
m
)
Vehicle Sham TF1
5mg/kg
TF1
10mg/kg
TF1
20mg/kg
Nimodipine
￿
￿
￿
￿
￿
￿
￿
￿
(b)
Figure 5: (a) The mRNA expression of COX-2 was assessed by using RT-PCR as standardized by coamplifying the housekeeping gene β-
actin. Lanes 1–7: Marker, Vehicle, Sham, TF1 (5mg · kg
−1), TF1 (10mg · kg
−1), TF1 (20mg · kg
−1), Nimodipine. (b) Statistical analysis
revealed that theaﬂavin-treatment markedly decreased mRNA expression of COX-2 dose dependently, ∗∗P<. 01.
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Figure 6: (a) The mRNA expression of iNOS was assessed by using RT-PCR as standardized by coamplifying the housekeeping gene β-actin.
Lanes 1–7: Marker, Vehicle, Sham, TF1 (5mg · kg
−1), TF1 (10mg · kg
−1), TF1 (20mg · kg
−1), Nimodipine. (b) Statistical analysis revealed
that theaﬂavin-treatment markedly decreased mRNA expression of iNOS dose dependently, ∗∗P<. 01.
with theaﬂavin and nimodipine reduced STAT-1 phosphory-
lationlevelsontyrosine701(Figure 7).Theaﬂavin-treatment
could reduce STAT-1 phosphorylation dose dependently.
Theseresultsdemonstratethattheaﬂavincouldhavetheabil-
ity to inhibit STAT-1 701 phosphorylation as well as protect
brain against I/R-induced inﬂammation.
DISCUSSION
In the current study theaﬂavin-treatment showed protec-
tive eﬀects on brain injuries induced by middle cerebral
artery occlusion followed by reperfusion in rats by blocking
inﬂammation-related events (MPO and ICAM-1) and ex-
pressions of prooxidative enzymes such as COX-2 and iNOS.
Further,theprotectiveeﬀectoftheaﬂavinwasassociatedwith
downregulation of STAT-1 phosphorylation. The neuronal
protective potential of theaﬂavin was dose dependently and
the eﬀect of 20mg/kg theaﬂavin was similar to that of ni-
modipine.
Rats subjected to cerebral ischemia-reperfusion showed
typical markers of cerebral inﬂammation and oxidative/ni-
trosative injury including leukocyte inﬁltration into the in-
farct area (enhanced MPO activity), upregulation of ad-
hesion molecules (ICAM-1), and induction of prooxida-
tive enzymes (COX-2 and iNOS) [36, 37]. Ischemia ac-
tivates a cascade that leads to the induction and expres-
sion of genes in a variety of cell types throughout the cen-
tral nervous system (CNS). COX-2, one product of such
immediate early genes, has become the focus of attention
because it is the rate-limiting enzyme involved in arachi-
donic acid metabolism, thereby generating prostaglandins
and thromboxanes which play important roles in support-
ing and sustaining the inﬂammatory response [38]. In ro-
dents as well as in humans, cerebral ischemia upregu-
lated COX-2 expression in neurons, blood vessels, and in-
ﬂammatory cells in the injured brain [13, 39, 40]. More-
over, administration of the selective COX-2 inhibitor NS398
attenuated the elevation of PGE2 and reduced the in-
farct in a model of MCAO [13]. COX-2 reaction prod-
ucts may also contribute to NMDA-induced neuronal in-
jury and the pathogenesis of nitric oxide after ischemia
[41, 42].Fei Cai et al 7
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Figure 7:(a)WesternblottingshowedlevelsofSTAT-1inbraintissueofrats.Lanes1–6:Vehicle,Sham,TF1(5mg·kg
−1),TF1(10mg·kg
−1),
TF1(20mg· kg
−1),Nimodipine.(b)Statisticalanalysisrevealedthattheaﬂavin-treatmentmarkedlydecreasedSTAT-1phosphorylationdose
dependently, ∗P<. 05, ∗∗P<. 01.
Nitric oxide (NO) is an important mediator in the cere-
bral ischemic injury [43]. Speciﬁcally, Nitric oxide derived
from the inducible isoform (iNOS) expressed by many cells
is very important in excitotoxic injury cascades [18, 19].
Pharmacologically selective inhibitors of iNOS attenuated
infarct volume after focal cerebral ischemia [21, 44, 45].
Nitric oxide produced by iNOS has been shown to con-
tribute to COX-2 activity (possibly without altering COX-
2 expression) [17]. Inhibition of iNOS could also serve as
neuroprotection through COX-2 inhibition just before the
start of the delayed death of CA1 neurons [46]. We con-
ﬁrmed that cortex tissue obtained from rats with 2hours
of MCAO followed 24hours reperfusion exhibited signiﬁ-
cantly more COX-2 and iNOS protein expressions than that
of sham group, which supported the idea that inﬂamma-
tory molecules participate in the occurrence and develop-
ment of cerebral ischemia. At the same time, we found that
theaﬂavin-treatment dose dependently inhibited COX-2 and
iNOS protein expressions.
In order to elucidate the mechanism of theaﬂavin on
inﬂammation-related events, we investigated the mRNA ex-
pression of COX-2 and iNOS in cerebral ischemic tissues of
rats and determined the inﬂuence of theaﬂavin-treatment
on mRNA production of COX-2 and iNOS. We found that
the mRNA expressions of COX-2 and iNOS were in accor-
dance with the results of immunohistochemistry detection.
RT-PCR analysis revealed that the mRNA levels of COX-2
and iNOS increased in brain tissues of the vehicle-treated
group. Similarly, theaﬂavin had a dose-dependent eﬀect on
decreasing mRNA expressions of COX-2 and iNOS. This
prompted us to investigate the regulation of COX-2 and
iNOS gene transcriptions in the process of inﬂammatory re-
sponses.
Many cytokines such as IL-6, IL-11, and inﬂammatory
mediators produced by ischemic brain cells, play impor-
tant roles contributing to ischemic pathophysiology [47, 48].
JAK-STAT is an important downstream signal pathway of
these cytokines [49]. Binding of neurokines to the mem-
brane receptor leads to dimerization of gp130, followed by
activation of JAK, which in turn phosphorylates cytoplasmic
STAT. Phosphorylated STAT forms homo- or heterodimers
andtranslocatesintothenucleus,stimulatinggenetranscrip-
tion. Therefore, the JAK-STAT pathway provides cells with a
vitalmechanismforrespondingtovariousextracellularstim-
uli including ischemic stress. Accumulation in the nucleus of
tyrosine phosphorylated STAT dimers is followed by DNA
binding, activation of target gene transcription, dephospho-
rylation, and returns to the cytoplasm [50]. STAT-1 induces
expressionofthetranscriptionfactorIRF-1,whichthenitself
binds to speciﬁc DNA elements of the iNOS promoter to fur-
ther promote iNOS expression [51]. Pretreatment with the
Janus tyrosine kinase (JAK) inhibitor AG-490 before the six
occlusion-reperfusion cycles blocked both the tyrosine phos-
phorylation of STAT1/3 and the subsequent upregulation of
COX-2 protein, demonstrating a necessary role of the JAK-
STAT pathway in the induction of COX-2 [52]. We there-
foreinvestigatedtheeﬀectoftheaﬂavinontyrosinephospho-
rylation of STAT-1. Our results have shown that the levels
of STAT-1 phosphorylation on tyrosine 701 were markedly
enhanced in brains subjected to 2h of MCAO followed
by 24hours reperfusion. Theaﬂavin-treatment dose depen-
dently inhibited phosphorylation of STAT-1 and mRNA ex-
pressions (COX-2 and iNOS) controlled by it.
In conclusion, our study demonstrated that theaﬂavin
signiﬁcantly protected neurons from cerebral ischemia-
reperfusion injury by limiting lipid peroxidation, leukocyte
inﬁltration and expression of ICAM-1. Theaﬂavin also sup-
pressed upregulations of inﬂammatory-related prooxidative
enzymes (iNOS and COX-2) in ischemic brain via, at least in
part, reducing STAT-1 phosphorylation. As a potent antiox-
idativedrug,theaﬂavincouldbebeneﬁcialfortheprevention
and/or amelioration of cerebral ischemia-reperfusion injury.
Thus, the protection of neurons by theaﬂavin may provide
clinically beneﬁcial outcomes alone or in combination with
thrombolytic therapy.
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